Clinical Trial Results:
12 MONTHS CASE SERIES OPEN STUDY TO ASSESS THE SAFETY AND EFFICACY OF INTRAVITREAL INJECTION OF LUCENTIS (RANIBIZUMAB 0.5 MG) USED IN COMBINATION WITH VISUDYNE (VERTEPORFIN PDT) IN NAIVE SIBJECTS WITH SUBFOVEAL CNV SECONDARY TO AMD.
Summary
|
|
EudraCT number |
2007-006235-31 |
Trial protocol |
IT |
Global completion date |
27 Oct 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
27 May 2022
|
First version publication date |
27 May 2022
|
Other versions |
|
Summary report(s) |
12 MONTHS CASE SERIES OPEN STUDY TO ASSESS THE SAFETY AND EFFICACY OF INTRAVITREAL INJECTION OF LUCENTIS (RANIBIZUMAB 0.5 MG) USED IN COMBINATION WITH VISUDYNE (VERTEPORFIN PDT) IN NAIVE SIBJECTS WITH |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.